2024 - The Incretin Impact: A New Era in Metabolic Disease and Obesity Drug Development

With the demonstrated efficacy and approvals of recent incretin-based therapies for the treatment of diabetes and obesity, one might think this is it for incretins. But really, it is just the beginning — given the possibilities for new combinations, different formulations and more indications throughout metabolic diseases and beyond.
What are incretins and how do they really work? How can we better understand their effects and advance drug development in obesity and metabolic disease? What will the future of incretin-based drug development look like?
It is currently a very exciting time within drug development for incretins, but there is still a lot we do not know. In this webinar, the expert speakers will cover how incretins were discovered, what we know about them, current challenges facing incretin drug development and some of the exciting work that is ongoing in this space. They will also discuss how advanced imaging techniques like magnetic resonance imaging (MRI) and positron emission tomography (PET) can give us insights that will help us to better understand incretins, as well as provide relevant information for future drug development.
Register for this webinar today to learn about incretins, the current status of incretin drug development and the speakers’ perspectives on the future of incretin drug development.
Keywords: Metabolic Disease, Glucagon, GIP, Incretins, Weight Loss Drug, Clinical Trial Imaging, Muscle Assessment, Diabetes Drug, GLP-1, Body Composition, PET, Weight Loss, Clinical Trials, Imaging, Therapeutic Areas, Medical Imaging, Biomarkers, Type 2 Diabetes, Clinical Research, MRI, Drug Development, Diabetes, Obesity